Published in Cell on May 31, 1991
FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell (2011) 8.46
Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron (2008) 6.26
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet (2003) 5.51
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A (1997) 4.73
Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A (1997) 4.03
The fragile-X premutation: a maturing perspective. Am J Hum Genet (2004) 3.89
FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med (2001) 3.84
A unified genetic theory for sporadic and inherited autism. Proc Natl Acad Sci U S A (2007) 3.47
Replication fork stalling at natural impediments. Microbiol Mol Biol Rev (2007) 3.47
Comparative genomics and molecular dynamics of DNA repeats in eukaryotes. Microbiol Mol Biol Rev (2008) 3.35
Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell (2010) 3.08
Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature (2008) 2.98
FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature (2012) 2.95
Identification of two KH domain proteins in the alpha-globin mRNP stability complex. EMBO J (1995) 2.87
Anticipation in myotonic dystrophy: new light on an old problem. Am J Hum Genet (1992) 2.85
Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet (1995) 2.77
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet (2009) 2.76
FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol (2007) 2.75
The fragile X syndrome d(CGG)n nucleotide repeats form a stable tetrahelical structure. Proc Natl Acad Sci U S A (1994) 2.72
Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet (2003) 2.71
Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol (2008) 2.46
Fragile X syndrome: diagnostic and carrier testing. Genet Med (2005) 2.45
Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol (2012) 2.42
MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol (2008) 2.39
A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med (1999) 2.36
Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet (2010) 2.36
Trinucleotide repeats associated with human disease. Nucleic Acids Res (1997) 2.35
Specific sequences in the fragile X syndrome protein FMR1 and the FXR proteins mediate their binding to 60S ribosomal subunits and the interactions among them. Mol Cell Biol (1996) 2.26
Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein. Mol Cell Biol (2000) 2.18
Simple tandem DNA repeats and human genetic disease. Proc Natl Acad Sci U S A (1995) 2.18
The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci (2012) 2.16
Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet (2009) 2.12
Self-association of the single-KH-domain family members Sam68, GRP33, GLD-1, and Qk1: role of the KH domain. Mol Cell Biol (1997) 2.11
Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA (2002) 2.06
The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J (1995) 2.05
Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. Genome Res (2012) 2.04
Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. Gene (2007) 2.01
Molecular heterogeneity of the fragile X syndrome. Nucleic Acids Res (1991) 2.00
The fragile X syndrome. J Med Genet (1998) 2.00
Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med (2011) 1.96
Quantitative comparison of FMR1 gene expression in normal and premutation alleles. Am J Hum Genet (1995) 1.91
An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. J Mol Diagn (2005) 1.91
A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem (2010) 1.86
Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet (2001) 1.85
Fragile-X syndrome: unique genetics of the heritable unstable element. Am J Hum Genet (1992) 1.85
Evidence for anticipation in schizophrenia. Am J Hum Genet (1994) 1.85
Mutations in the gene encoding the Sigma 2 subunit of the adaptor protein 1 complex, AP1S2, cause X-linked mental retardation. Am J Hum Genet (2006) 1.85
A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases. Am J Hum Genet (1994) 1.84
Identification of AUF1 (heterogeneous nuclear ribonucleoprotein D) as a component of the alpha-globin mRNA stability complex. Mol Cell Biol (1997) 1.83
Fragile X mental retardation protein regulates translation by binding directly to the ribosome. Mol Cell (2014) 1.83
The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci (2013) 1.81
Fragile X syndrome. Eur J Hum Genet (2008) 1.81
FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology (2007) 1.80
FMR1: a gene with three faces. Biochim Biophys Acta (2009) 1.77
DNA methylation and its basic function. Neuropsychopharmacology (2012) 1.76
Repeat polymorphisms within gene regions: phenotypic and evolutionary implications. Am J Hum Genet (2000) 1.75
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord (2012) 1.73
A microdeletion of less than 250 kb, including the proximal part of the FMR-I gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome. Am J Hum Genet (1992) 1.73
Gonosomal mosaicism in myotonic dystrophy patients: involvement of mitotic events in (CTG)n repeat variation and selection against extreme expansion in sperm. Am J Hum Genet (1994) 1.71
Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats FRAXAC1 and FRAXAC2 which immediately flank the fragile site. J Med Genet (1991) 1.71
Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet (1993) 1.71
Genetic modifiers of tauopathy in Drosophila. Genetics (2003) 1.70
Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry (2010) 1.69
CGG repeat in the FMR1 gene: size matters. Clin Genet (2011) 1.68
Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet (1993) 1.68
FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet (2005) 1.67
Fragile X gene instability: anchoring AGGs and linked microsatellites. Am J Hum Genet (1995) 1.61
FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J (1995) 1.61
Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am J Hum Genet (2002) 1.59
CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem (2008) 1.59
Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol (2010) 1.59
Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations. Am J Hum Genet (2000) 1.59
Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev (2006) 1.58
Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J (2010) 1.58
TRDB--the Tandem Repeats Database. Nucleic Acids Res (2006) 1.57
A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One (2008) 1.57
Mental status of females with an FMR1 gene full mutation. Am J Hum Genet (1996) 1.57
Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci U S A (1992) 1.56
Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep (2014) 1.55
Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science (2014) 1.54
A nuclear role for the Fragile X mental retardation protein. EMBO J (1996) 1.54
FMR1 fully expanded mutation with minimal methylation in a high functioning fragile X male. J Med Genet (1996) 1.54
Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet (1994) 1.54
Familial transmission of the FMR1 CGG repeat. Am J Hum Genet (1996) 1.53
Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet (1997) 1.53
Drosophila fragile X mental retardation protein developmentally regulates activity-dependent axon pruning. Development (2008) 1.52
Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron (2012) 1.52
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Triplet repeat expansion at the FRAXE locus and X-linked mild mental handicap. Am J Hum Genet (1994) 1.51
Localized Bicaudal-C RNA encodes a protein containing a KH domain, the RNA binding motif of FMR1. EMBO J (1995) 1.50
Linkage disequilibrium between the fragile X mutation and two closely linked CA repeats suggests that fragile X chromosomes are derived from a small number of founder chromosomes. Am J Hum Genet (1993) 1.50
FRAXA and FRAXE: the results of a five year survey. J Med Genet (2000) 1.50
Fragile X and X-linked intellectual disability: four decades of discovery. Am J Hum Genet (2012) 1.50
Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation. J Med Genet (1992) 1.49
Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet (1993) 1.47
Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res (2006) 1.47
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res (2002) 1.47
Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Nat Neurosci (2013) 1.46
Autism: a "critical period" disorder? Neural Plast (2011) 1.46
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Positional cloning of the Werner's syndrome gene. Science (1996) 10.98
Alu polymerase chain reaction: a method for rapid isolation of human-specific sequences from complex DNA sources. Proc Natl Acad Sci U S A (1989) 8.68
An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science (1992) 8.20
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet (2007) 6.29
An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science (2001) 6.07
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet (1997) 4.65
Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell (2001) 4.25
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons. Neuron (1999) 3.69
A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature (1991) 3.59
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee--the MOVE consensus. Rheumatology (Oxford) (2004) 3.38
Triplet repeat mutations in human disease. Science (1992) 3.35
Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet (1997) 3.32
Characterization of a murine gene expressed from the inactive X chromosome. Nature (1991) 3.21
The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics (1989) 3.10
Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Science (1993) 2.75
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet (1993) 2.69
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry (1991) 2.49
Lissencephaly. A human brain malformation associated with deletion of the LIS1 gene located at chromosome 17p13. JAMA (1993) 2.36
Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron (2001) 2.29
Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun (1995) 2.06
A novel gene causing a mendelian audiogenic mouse epilepsy. Neuron (2001) 2.05
Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl (1980) 1.99
Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet (1993) 1.95
Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphates. Nucleic Acids Res (1994) 1.95
De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry (2013) 1.93
Pentanucleotide repeat length polymorphism at the human CD4 locus. Nucleic Acids Res (1991) 1.85
Characterization of nit-2, the major nitrogen regulatory gene of Neurospora crassa. Mol Cell Biol (1987) 1.73
Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol (1997) 1.72
Exercise induced critical ischaemia of the upper limb secondary to a cervical rib. Br J Sports Med (2003) 1.72
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol (1991) 1.70
Gender differences in symptom presentation associated with coronary heart disease. Am J Cardiol (1999) 1.69
Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child (1987) 1.68
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers. Diabetes Educ (2000) 1.65
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord (2004) 1.64
The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator. Mol Cell Biol (1994) 1.62
Therapeutic interventions for Burkitt's lymphoma in children. Cochrane Database Syst Rev (2006) 1.61
Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit. EMBO J (1997) 1.59
Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring. JAMA (1993) 1.58
AphidBase: a centralized bioinformatic resource for annotation of the pea aphid genome. Insect Mol Biol (2010) 1.57
Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. Am J Med Genet B Neuropsychiatr Genet (2004) 1.56
Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet (2003) 1.53
32P-incorporation PCR for the detection of rearrangements at the TCR-gamma locus. Diagn Mol Pathol (1996) 1.52
Mutations in the consensus helicase domains of the Werner syndrome gene. Werner's Syndrome Collaborative Group. Am J Hum Genet (1997) 1.52
Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology (2001) 1.51
nit-4, a pathway-specific regulatory gene of Neurospora crassa, encodes a protein with a putative binuclear zinc DNA-binding domain. Mol Cell Biol (1991) 1.50
Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol (1992) 1.48
Characterization of mutations in Gaucher patients by cDNA cloning. Am J Hum Genet (1989) 1.48
Folding of proteins with WD-repeats: comparison of six members of the WD-repeat superfamily to the G protein beta subunit. Biochemistry (1996) 1.48
Three cases of triploidy in man. Cytogenetics (1967) 1.48
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol (2008) 1.48
Targeted mutagenesis of Lis1 disrupts cortical development and LIS1 homodimerization. Proc Natl Acad Sci U S A (2001) 1.44
Imprinting analysis of three genes in the Prader-Willi/Angelman region: SNRPN, E6-associated protein, and PAR-2 (D15S225E). Hum Mol Genet (1994) 1.44
A treatment for carpal tunnel syndrome: results of follow-up study. J Manipulative Physiol Ther (1994) 1.43
Spectrum of atrial septal defects associated with mutations of NKX2.5 and GATA4 transcription factors. J Med Genet (2005) 1.43
Validation studies of SNRPN methylation as a diagnostic test for Prader-Willi syndrome. Am J Med Genet (1996) 1.43
The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes (2001) 1.42
Antidepressant use over time in a rural older adult population: the MoVIES Project. J Am Geriatr Soc (1997) 1.42
Clinical examination of varicose veins--a validation study. Ann R Coll Surg Engl (2000) 1.42
Doublecortin, a stabilizer of microtubules. Hum Mol Genet (1999) 1.41
Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia (2009) 1.40
A complete YAC contig of the Prader-Willi/Angelman chromosome region (15q11-q13) and refined localization of the SNRPN gene. Genomics (1993) 1.38
The lissencephaly gene product Lis1, a protein involved in neuronal migration, interacts with a nuclear movement protein, NudC. Curr Biol (1998) 1.37
Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism. Mol Psychiatry (2009) 1.36
Analysis of the RELN gene as a genetic risk factor for autism. Mol Psychiatry (2005) 1.36
A locus for autosomal dominant keratoconus maps to human chromosome 3p14-q13. J Med Genet (2004) 1.36
Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet (2004) 1.35
The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region. Genome Res (1997) 1.34
SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family. Genomics (1997) 1.34
Light well: a tunable free-electron light source on a chip. Phys Rev Lett (2009) 1.32
Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann Neurol (2001) 1.31
Fine structure of the human FMR1 gene. Hum Mol Genet (1993) 1.30
Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia (2003) 1.28
The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol (2000) 1.28
Mouse/human sequence divergence in a region with a paternal-specific methylation imprint at the human H19 locus. Hum Mol Genet (1996) 1.27
The negative-acting NMR regulatory protein of Neurospora crassa binds to and inhibits the DNA-binding activity of the positive-acting nitrogen regulatory protein NIT2. Biochemistry (1995) 1.27
Doublecortin mutations cluster in evolutionarily conserved functional domains. Hum Mol Genet (2000) 1.24
Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates. Br J Cancer (2011) 1.24
Long survival in childhood lymphoblastic leukaemia. Br J Cancer (1987) 1.23
Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child (1990) 1.22
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J (2014) 1.22
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21